Measles, mumps and rubella vaccine

Measles, mumps and rubella vaccine
source
Name	Measles, mumps and rubella vaccine
Type	vaccine
Target	Measles, Mumps, Rubella
Tradename	MMR, MMR-II, Priorix
Routes	Subcutaneous, intramuscular
Owner	Various manufacturers

Measles, mumps and rubella vaccine is a combined live attenuated vaccine designed to prevent Measles, Mumps, and Rubella. It is administered to reduce morbidity and mortality associated with these viral diseases and to interrupt transmission in populations targeted by programs such as those run by the World Health Organization, Centers for Disease Control and Prevention, and national public health agencies like Public Health England. The vaccine is produced and distributed by manufacturers subject to regulatory approval by authorities including the Food and Drug Administration, the European Medicines Agency, and other national regulators.

Medical uses

The vaccine is indicated for routine childhood immunization recommended by entities such as the American Academy of Pediatrics, the Advisory Committee on Immunization Practices, and the Joint Committee on Vaccination and Immunisation. It is used for outbreak control directed by organizations including the World Health Organization, the Pan American Health Organization, and national ministries such as the Ministry of Health (New Zealand) and the Ministry of Health and Family Welfare (India). Travel clinics affiliated with International Air Transport Association, Centers for Disease Control and Prevention, and major hospitals like Mayo Clinic and Cleveland Clinic advise vaccination for travelers to regions with endemic transmission such as parts of Ukraine, Philippines, and historically affected areas including United Kingdom and United States. Special indications involve post-exposure prophylaxis strategies coordinated by local health departments and outbreak response units at institutions like the Bill & Melinda Gates Foundation-funded programs.

Composition and formulations

Formulations vary by manufacturer, including live attenuated strains derived from lineage sources developed in laboratories and institutions such as the Harvard Medical School-affiliated research groups and historical producers like Merck & Co. and GlaxoSmithKline. Typical formulations combine the Edmonston-derived measles strain, the Jeryl Lynn mumps strain, and the RA 27/3 rubella strain produced in tissue culture systems historically associated with institutions like the Wistar Institute and laboratories connected to the Rockefeller Foundation. Vaccine vials may contain stabilizers and preservatives approved by regulators such as the European Commission and the Food and Drug Administration, with manufacturing processes overseen by organizations like the World Health Organization prequalification program. Combination products are marketed under trade names including MMR-II, Priorix, and others licensed in markets governed by agencies such as the Medicines and Healthcare products Regulatory Agency.

Efficacy and immunogenicity

Clinical trials and observational studies published in journals associated with institutions like Johns Hopkins University, Stanford University, and the National Institutes of Health report seroconversion rates and effectiveness estimates. A two-dose schedule recommended by the Centers for Disease Control and Prevention achieves high effectiveness against Measles comparable to data from large cohort studies in Japan, Germany, and Canada; similar immunogenicity data are reported for Mumps and Rubella in trials coordinated by groups including the World Health Organization and academic centers like Imperial College London. Immunogenicity assessments use neutralization assays standardized by laboratories such as the European Centre for Disease Prevention and Control and reference panels from institutions like the National Institute for Biological Standards and Control. Herd immunity thresholds referenced in modeling studies from universities including Harvard University and University of Oxford inform policy decisions by bodies like the Advisory Committee on Immunization Practices.

Safety and adverse effects

Post-marketing surveillance is conducted by pharmacovigilance systems including the Vaccine Adverse Event Reporting System, the Yellow Card Scheme, and databases managed by the European Medicines Agency. Common mild adverse events described in product literature and surveillance reports from hospitals such as Massachusetts General Hospital include transient fever and injection-site reactions; rare adverse events have been characterized through studies at institutions like CDC and NIH. Safety reviews by panels convened by organizations such as the Institute of Medicine and regulatory decisions by the Food and Drug Administration address reported associations and causality assessments. Contraindications and precautions are listed by professional bodies including the American Academy of Pediatrics and national health services like NHS England.

Administration and schedule

Recommended schedules are promulgated by the World Health Organization, Centers for Disease Control and Prevention, and national advisory groups such as the National Advisory Committee on Immunization in Canada and the An Advisory Committee on Immunization Practices in the United States. Typical schedules include a first dose at 9–15 months depending on national policy and a second dose at 15–18 months or at school entry; catch-up schedules are outlined by agencies including the European Centre for Disease Prevention and Control for migrant and refugee populations. Administration is typically subcutaneous or intramuscular in clinical settings such as community clinics run by organizations like Red Cross and pediatric practices affiliated with institutions like Children's Hospital of Philadelphia.

History and development

Development involved contributions from researchers and institutions including John Enders-era laboratories, laboratories affiliated with Stanley Plotkin, and vaccine producers such as Eli Lilly and Company and later manufacturers like Merck & Co. and GlaxoSmithKline. Early measles vaccine work connected to laboratories like Harvard Medical School and the Wistar Institute evolved into combined formulations developed during the mid-20th century, with regulatory pathways traversing agencies such as the Food and Drug Administration and the European Medicines Agency. Global immunization campaigns supported by actors including the World Health Organization, the United Nations Children's Fund, and the Gavi, the Vaccine Alliance led to widespread adoption and integration into national immunization schedules across regions including Africa, Asia, and the Americas.

Public health impact and recommendations

Widespread use under programs coordinated by the World Health Organization, Centers for Disease Control and Prevention, and partnerships like UNICEF and Gavi, the Vaccine Alliance has contributed to dramatic declines in disease incidence, regional elimination efforts in areas overseen by the Pan American Health Organization, and rubella control strategies informing congenital rubella syndrome prevention spearheaded by agencies such as the European Centre for Disease Prevention and Control. Policy recommendations from bodies including the Advisory Committee on Immunization Practices and national ministries influence school-entry vaccination requirements and outbreak control measures implemented by public health departments like those in New York City, London, and Tokyo. Continued surveillance by institutions such as CDC and academic research at universities like Yale University informs updates to schedules, formulations, and recommendations.

Category:Vaccines